Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Passage Bio stock

PASG
US7027121000
A2P0EQ

Price

0.57
Today +/-
-0.09
Today %
-15.89 %

Passage Bio stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Passage Bio stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Passage Bio stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Passage Bio stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Passage Bio's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Passage Bio Stock Price History

DatePassage Bio Price
12/31/20240.57 undefined
12/30/20240.67 undefined
12/27/20240.66 undefined
12/26/20240.66 undefined
12/24/20240.65 undefined
12/23/20240.65 undefined
12/20/20240.66 undefined
12/19/20240.65 undefined
12/18/20240.61 undefined
12/17/20240.67 undefined
12/16/20240.72 undefined
12/13/20240.76 undefined
12/12/20240.78 undefined
12/11/20240.76 undefined
12/10/20240.79 undefined
12/9/20240.80 undefined
12/6/20240.78 undefined
12/5/20240.71 undefined
12/4/20240.75 undefined

Passage Bio Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Passage Bio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Passage Bio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Passage Bio’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Passage Bio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Passage Bio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Passage Bio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Passage Bio’s growth potential.

Passage Bio Revenue, EBIT and net profit per share

DatePassage Bio RevenuePassage Bio EBITPassage Bio Net Income
2029e262.7 M undefined115.06 M undefined169.17 M undefined
2028e119.93 M undefined5.88 M undefined70.57 M undefined
2027e34.43 M undefined-51.74 M undefined-4.1 M undefined
2026e408,000 undefined-78.64 M undefined-46.73 M undefined
2025e0 undefined-67.67 M undefined-41.46 M undefined
2024e0 undefined-71.63 M undefined-60.11 M undefined
20230 undefined-103 M undefined-102.06 M undefined
20220 undefined-138.39 M undefined-136.13 M undefined
20210 undefined-185.73 M undefined-185.39 M undefined
20200 undefined-112.9 M undefined-112.23 M undefined
20190 undefined-37.19 M undefined-45.63 M undefined
20180 undefined-13.47 M undefined-12.77 M undefined

Passage Bio Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e2029e
00000000034119262
----------250.00120.17
------------
000000000000
-12-45-112-185-136-102-60-41-46-470169
-275.00148.8965.18-26.49-25.00-41.18-31.6712.20-91.30-1,850.00141.43
39.439.438.6253.3454.4354.74000000
------------
Details

Keystats

ⓘ

Revenue and Growth

The Passage Bio Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Passage Bio is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201820192020202120222023
           
24.9158.9304.8315.8189.6114.29
000000
000000
000000
8.56.912.49.37.43.67
33.4165.8317.2325.1197117.96
01.12.823.842.232.15
000000
000000
000000
000000
011.886.24.30.43
012.910.83046.532.59
33.4178.7328355.1243.5150.55
           
43.1230.60000.01
0.92.4475.6675.3694.7705.79
-13-58.7-170.9-356.3-492.4-594.47
000-0.4-1-0.04
000000
31174.3304.7318.6201.3111.28
0.20.65.39.44.11.3
0.1315.419.414.213.04
000.50.70.12
000000
000000
0.33.621.229.518.416.34
000000
000000
2.20.62.16.923.822.92
2.20.62.16.923.822.92
2.54.223.336.442.239.26
33.5178.5328355243.5150.55
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Passage Bio provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Passage Bio's financial health and stability.

Assets

Passage Bio's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Passage Bio must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Passage Bio after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Passage Bio's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201820192020202120222023
-12-45-112-185-136-102
000133
000000
-8-51411-85
21116452214
000000
000000
-18-39-80-126-118-78
-2-1-1-25-50
-2-1-172-452565
00-170-203065
000000
000000
4517622816600
45175228166-10
-----1.00-
000000
24134-23-6-94-12
-21.11-41.59-82.17-152.52-123.48-78.41
000000

Passage Bio stock margins

The Passage Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Passage Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Passage Bio.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Passage Bio's sales revenue. A higher gross margin percentage indicates that the Passage Bio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Passage Bio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Passage Bio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Passage Bio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Passage Bio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Passage Bio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Passage Bio Margin History

Passage Bio Gross marginPassage Bio Profit marginPassage Bio EBIT marginPassage Bio Profit margin
2029e0 %43.8 %64.4 %
2028e0 %4.9 %58.84 %
2027e0 %-150.3 %-11.9 %
2026e0 %-19,274.25 %-11,453.24 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %

Passage Bio Stock Sales Revenue, EBIT, Earnings per Share

The Passage Bio earnings per share therefore indicates how much revenue Passage Bio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Passage Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Passage Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Passage Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Passage Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Passage Bio Revenue, EBIT and net profit per share

DatePassage Bio Sales per SharePassage Bio EBIT per sharePassage Bio Earnings per Share
2029e4.25 undefined0 undefined2.74 undefined
2028e1.94 undefined0 undefined1.14 undefined
2027e0.56 undefined0 undefined-0.07 undefined
2026e0.01 undefined0 undefined-0.76 undefined
2025e0 undefined0 undefined-0.67 undefined
2024e0 undefined0 undefined-0.97 undefined
20230 undefined-1.88 undefined-1.86 undefined
20220 undefined-2.54 undefined-2.5 undefined
20210 undefined-3.48 undefined-3.48 undefined
20200 undefined-2.92 undefined-2.91 undefined
20190 undefined-0.94 undefined-1.16 undefined
20180 undefined-0.34 undefined-0.32 undefined

Passage Bio business model

Passage Bio Inc is a biopharmaceutical company focused on the treatment of rare genetic diseases. The company is headquartered in Pennsylvania, USA and was founded in 2018. The beginnings of Passage Bio Inc can be traced back to the work of the Penn Medicine Gene Therapy Program, which has been focusing on researching gene therapies for rare diseases for many years. In 2018, the company was finally founded to bring the research results to the market and help patients with rare diseases. Passage Bio's business model is to develop and market gene therapies based on AAV (Adeno-associated viruses). These viruses are injected into the body and are used to transport healthy genes into cells to replace defective or diseased genes. This can restore the production of missing or damaged proteins, which can contribute to symptom relief and disease cure. The company specializes in developing gene therapies for rare, monogenic diseases that are often caused by a single genetic defect. Such diseases are often difficult to treat and have no effective therapies. Therefore, gene therapies can be a promising option to help patients with these diseases. Passage Bio currently has four gene therapy candidates in its pipeline, all focusing on rare neurological diseases. The first candidate, PBGM01, aims to treat GM1 gangliosidosis, a genetic disorder that leads to impairment of the nervous system and often severe impairment of intellectual and physical development. The other candidates focus on treating diseases such as Krabbe disease, frontotemporal dementia, and Niemann-Pick disease type A. Passage Bio has also partnered with Catalent to support the manufacturing and packaging of its gene therapy products. The two companies are working together to develop a scalable production platform for gene therapy manufacturing, which will enable Passage Bio to produce and distribute therapies on a large scale. Overall, Passage Bio has the potential to change the lives of many patients with rare diseases. By developing gene therapies based on AAV technology, the company can create a promising therapy option for patients who currently have no other options available. With a dedicated team of researchers and development specialists, the company is working hard to develop new gene therapies that can contribute to the relief and cure of rare and serious diseases. Passage Bio is one of the most popular companies on Eulerpool.com.

Passage Bio SWOT Analysis

Strengths

Passage Bio Inc has several strengths that help position it as a strong player in the market. One major strength is its robust pipeline of gene therapies targeting rare monogenic CNS disorders. This pipeline includes multiple programs at different stages of development, providing significant growth potential for the company.

Additionally, Passage Bio Inc benefits from strong financial backing and strategic partnerships. It has secured substantial funding from strategic investors, allowing it to advance its research and development activities. Moreover, its partnerships with leading academic institutions and organizations further enhance its scientific capabilities and knowledge base.

Weaknesses

Despite its strengths, Passage Bio Inc also faces certain weaknesses that may pose challenges. One weakness is its heavy reliance on a limited number of product candidates. Since its pipeline is primarily focused on gene therapies for rare CNS disorders, the failure or delays in clinical trials or regulatory approvals of these candidates could significantly impact the company's prospects.

Additionally, Passage Bio Inc operates in a highly competitive market where other biopharmaceutical companies are actively pursuing gene therapy research. This increased competition puts pressure on the company to differentiate itself and effectively communicate the value of its therapies to healthcare professionals, patients, and investors.

Opportunities

Passage Bio Inc has several opportunities to leverage its strengths and expand its market presence. One opportunity lies in the increasing acceptance and adoption of gene therapies for the treatment of rare monogenic CNS disorders. As the regulatory landscape becomes more favorable and healthcare systems acknowledge the long-term benefits of gene therapies, Passage Bio Inc can capitalize on this trend.

Moreover, the company has the potential to explore partnerships and collaborations to further enhance its pipeline and scientific capabilities. By forging strategic alliances with academic institutions, biotechnology companies, or pharmaceutical giants, Passage Bio Inc can access additional resources and expertise, accelerate the development of its therapies, and tap into new markets.

Threats

Passage Bio Inc faces various threats that require careful consideration and proactive measures. One significant threat is the possibility of regulatory challenges or obstacles during the clinical trial and approval processes. Delays or denials in obtaining regulatory approvals can significantly impede the commercialization and revenue generation of Passage Bio Inc's gene therapies.

Additionally, the rapidly evolving scientific landscape involving gene therapies poses a threat. New discoveries or breakthroughs by competitor companies could potentially render Passage Bio Inc's therapies less effective or obsolete. Staying at the forefront of scientific advancements and continuously innovating is crucial to maintain sustainable competitive advantage.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Passage Bio Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Passage Bio historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Passage Bio shares outstanding

The number of shares was Passage Bio in 2024 — This indicates how many shares 54.743 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Passage Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Passage Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Passage Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Passage Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Passage Bio.

Passage Bio latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.23 -0.31  (-32.14 %)2024 Q3
6/30/2024-0.32 -0.26  (17.77 %)2024 Q2
3/31/2024-0.36 -0.3  (17.72 %)2024 Q1
12/31/2023-0.41 -0.3  (26.79 %)2023 Q4
9/30/2023-0.47 -0.49  (-5.31 %)2023 Q3
6/30/2023-0.49 -0.44  (9.82 %)2023 Q2
3/31/2023-0.51 -0.63  (-24.7 %)2023 Q1
12/31/2022-0.53 -0.49  (8.1 %)2022 Q4
9/30/2022-0.81 -0.49  (39.26 %)2022 Q3
6/30/2022-0.84 -0.73  (13.41 %)2022 Q2
1
2

Eulerpool ESG Scorecard© for the Passage Bio stock

Eulerpool World ESG Rating (EESG©)

50/ 100

🌱 Environment

51

👫 Social

71

🏛️ Governance

27

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Passage Bio shareholders

%
Name
Stocks
Change
Date
16.00315 % OrbiMed Advisors, LLC9,885,145-239,4319/19/2024
13.64247 % Lynx1 Capital Advisors LLC8,426,9553,369,3268/7/2024
9.79764 % Vestal Point Capital, LP6,052,0001,552,0006/30/2024
4.04391 % New Leaf Venture Partners LLC2,497,92206/30/2024
3.35363 % The Vanguard Group, Inc.2,071,53806/30/2024
2.42836 % Tang Capital Management, LLC1,500,00006/30/2024
1.82220 % Renaissance Technologies LLC1,125,574-79,9506/30/2024
1.55621 % Acadian Asset Management LLC961,27106/30/2024
1.22248 % BlackRock Institutional Trust Company, N.A.755,12834,1736/30/2024
1.21568 % Millennium Management LLC750,926-114,8136/30/2024
1
2
3
4
5
...
10

Passage Bio Executives and Management Board

Mr. Edgar Cale

(59)
Passage Bio General Counsel, Company Secretary
Compensation 1.42 M

Mr. William Chou

(50)
Passage Bio President, Chief Executive Officer, Director (since 2022)
Compensation 1.3 M

Dr. Maxine Gowen

(65)
Passage Bio Independent Chairwoman of the Board (since 2021)
Compensation 266,638

Dr. Michael Kamarck

(72)
Passage Bio Independent Director
Compensation 111,466

Mr. Sandip Kapadia

(53)
Passage Bio Independent Director
Compensation 86,094
1
2
3

Passage Bio Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Catalent Stock
Catalent
SupplierCustomer0,710,270,680,830,62-0,22
1

Most common questions regarding Passage Bio

What values and corporate philosophy does Passage Bio represent?

Passage Bio Inc is a renowned biotechnology company that values innovation, scientific excellence, and patient-centered approaches. At its core, Passage Bio is committed to developing transformative gene therapies to address severe neurological disorders. The company's corporate philosophy revolves around collaboration, integrity, and a deep commitment to improving patient outcomes. With a strong focus on cutting-edge research and development, Passage Bio consistently aims to revolutionize treatment options for patients in need. By leveraging its expertise and advanced technologies, Passage Bio Inc strives to make a positive impact in the lives of individuals suffering from devastating and currently untreatable genetic disorders.

In which countries and regions is Passage Bio primarily present?

Passage Bio Inc is primarily present in the United States.

What significant milestones has the company Passage Bio achieved?

Passage Bio Inc has achieved significant milestones in its journey. The company successfully completed its initial public offering (IPO) in February 2020. In the same year, Passage Bio entered into a collaboration agreement with the University of Pennsylvania (UPenn) to advance innovative gene therapies for rare monogenic CNS disorders. Additionally, the company received Fast Track designation from the U.S. FDA for its lead product candidate, PBGM01, designed to treat patients with GM1 gangliosidosis. Passage Bio has also expanded its pipeline to include therapies for other rare genetic disorders. These achievements demonstrate Passage Bio Inc's commitment to advancing groundbreaking gene therapies and providing potential treatment options for patients in need.

What is the history and background of the company Passage Bio?

Passage Bio Inc is a biotechnology company specializing in genetic medicines for rare, debilitating diseases. Founded in 2017, Passage Bio aims to develop transformative therapies utilizing its proprietary Passage Bio Knowledge Platform. The company focuses on creating gene therapies capable of addressing the underlying genetic cause of diseases. With a team of seasoned experts and strategic collaborations, Passage Bio strives to deliver innovative treatments for patients with severe genetic disorders. By harnessing the potential of genetic medicine, Passage Bio Inc aspires to revolutionize the field and improve the lives of individuals affected by rare diseases.

Who are the main competitors of Passage Bio in the market?

The main competitors of Passage Bio Inc in the market include companies such as bluebird bio, Avrobio, and Avexis.

In which industries is Passage Bio primarily active?

Passage Bio Inc is primarily active in the biotechnology industry.

What is the business model of Passage Bio?

The business model of Passage Bio Inc revolves around developing transformative therapies for rare monogenic central nervous system (CNS) disorders. The company utilizes a cutting-edge platform technology called AAV-Delivered Gene Therapy, which aims to correct genetic mutations responsible for certain CNS diseases. Passage Bio Inc's strategic approach involves collaborating with leading research centers, academic institutions, and industry experts to advance potential treatments. By focusing on precision medicine, the company aims to provide innovative gene therapies that target the root cause of these rare diseases. Passage Bio Inc is committed to improving the lives of patients affected by CNS disorders through its research and development efforts.

What is the P/E ratio of Passage Bio 2025?

The Passage Bio P/E ratio is -0.75.

What is the P/S ratio of Passage Bio 2025?

The Passage Bio P/S ratio is 0.

What is the Quality Investing of Passage Bio?

The Quality Investing for Passage Bio is 1/10.

What is the revenue of Passage Bio 2025?

The revenue cannot currently be calculated for Passage Bio.

How high is the profit of Passage Bio 2025?

The expected Passage Bio profit is -41.46 M USD.

What is the business model of Passage Bio

Passage Bio Inc is a biopharmaceutical company focused on developing innovative gene therapy products for rare, genetic diseases. The company collaborates closely with leading academic and industrial partners to advance its research and development programs. The business models of Passage Bio Inc are diverse and include both the development of its own products and collaborations with other companies and institutions to develop new therapies for a broader range of diseases. The company works closely with patient groups to ensure that its products are tailored to the needs and requirements of the patients. The key products of Passage Bio Inc are gene therapies that aim to treat the underlying genetic causes of various diseases. Their products are designed to correct the absence or malfunction of one or more genes in specific body cells to restore or improve the normal function of the affected tissue. Due to their expertise and experience in the development of gene therapy products, Passage Bio's business areas have focused on various therapy areas. The company's products and services currently include gene therapies for monogenic diseases of the nervous system such as frontotemporal dementia (FTD) and Krabbe disease. Furthermore, the company continues to expand its pipeline of gene therapy products for various other medical conditions. Passage Bio Inc adopts an innovative approach to the development of gene therapy treatments and is interested in developing new and effective methods for the production, delivery, and administration of gene therapies. The company also engages in various collaborations with other companies and institutions to develop and bring to market new therapies for a broader range of diseases. In line with its business model, Passage Bio Inc combines its own research and development projects with collaborations with other companies and institutions. The company works closely with patient groups to develop its products according to the needs and requirements of the patients. Another important aspect of Passage Bio Inc's business model is its close collaboration with leading academic and industrial partners to provide a broader range of gene therapy products and services. In summary, the business model of Passage Bio Inc aims to develop innovative gene therapy products for rare genetic diseases. The company engages in research and development of its own products but also collaborates closely with other companies and institutions to develop new therapies for a broader range of diseases. The close collaboration with patient groups and leading academic and industrial partners is an important component of Passage Bio Inc's business model.

What is the Passage Bio dividend?

Passage Bio pays a dividend of 0 USD distributed over payouts per year.

How often does Passage Bio pay dividends?

The dividend cannot currently be calculated for Passage Bio or the company does not pay out a dividend.

What is the Passage Bio ISIN?

The ISIN of Passage Bio is US7027121000.

What is the Passage Bio WKN?

The WKN of Passage Bio is A2P0EQ.

What is the Passage Bio ticker?

The ticker of Passage Bio is PASG.

How much dividend does Passage Bio pay?

Over the past 12 months, Passage Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Passage Bio is expected to pay a dividend of 0 USD.

What is the dividend yield of Passage Bio?

The current dividend yield of Passage Bio is .

When does Passage Bio pay dividends?

Passage Bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Passage Bio?

Passage Bio paid dividends every year for the past 0 years.

What is the dividend of Passage Bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Passage Bio located?

Passage Bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von Passage Bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Passage Bio from 1/2/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/2/2025.

When did Passage Bio pay the last dividend?

The last dividend was paid out on 1/2/2025.

What was the dividend of Passage Bio in the year 2024?

In the year 2024, Passage Bio distributed 0 USD as dividends.

In which currency does Passage Bio pay out the dividend?

The dividends of Passage Bio are distributed in USD.

All fundamentals about Passage Bio

Our stock analysis for Passage Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Passage Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.